| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 002399 from our risk checks.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.65 |
| 52 Week High | CN¥12.97 |
| 52 Week Low | CN¥6.89 |
| Beta | 0.40 |
| 11 Month Change | 1.37% |
| 3 Month Change | -3.60% |
| 1 Year Change | -12.43% |
| 33 Year Change | -38.18% |
| 5 Year Change | -53.58% |
| Change since IPO | -82.37% |
Recent News & Updates
Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio
Aug 22
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Recent updates
Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio
Aug 22Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues
May 06Shareholder Returns
| 002399 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -2.9% | -2.8% |
| 1Y | -12.4% | -10.1% | -18.4% |
Return vs Industry: 002399 underperformed the CN Pharmaceuticals industry which returned -8.8% over the past year.
Return vs Market: 002399 exceeded the CN Market which returned -17.4% over the past year.
Price Volatility
| 002399 volatility | |
|---|---|
| 002399 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 002399 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002399's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,080 | Yu Shan | www.hepalink.com |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002399 fundamental statistics | |
|---|---|
| Market cap | CN¥12.79b |
| Earnings (TTM) | -CN¥694.76m |
| Revenue (TTM) | CN¥5.52b |
2.6x
P/S Ratio-20.4x
P/E RatioIs 002399 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002399 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.52b |
| Cost of Revenue | CN¥4.55b |
| Gross Profit | CN¥964.60m |
| Other Expenses | CN¥1.66b |
| Earnings | -CN¥694.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 17.48% |
| Net Profit Margin | -12.59% |
| Debt/Equity Ratio | 40.0% |
How did 002399 perform over the long term?
See historical performance and comparison